Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors.
Authors
Li-Yuan Bai
China Medical University Hospital, China Medical University, Taichung, Taiwan
Li-Yuan Bai , Nai-Jung Chiang , Chih-Hung Hsu , Yi-Hsin Liang , Chang-Fang Chiu , Ching-Chan Lin , Kwang-Yu Chang , Shang-Hung Chen , Hui-Jen Tsai , Yu-Ping Lin , Li-Tzong Chen , Chia-Chi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT 03810742
DOI
10.1200/JCO.2022.40.4_suppl.660
Abstract #
660
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 dose-finding trial of cabozantinib (cabo) and trifluridine/tipiracil (FDT/TPI) in metastatic colorectal carcinoma (mCRC).
First Author: Farshid Dayyani
Poster
2018 Gastrointestinal Cancers Symposium
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
First Author: Shigenori Kadowaki
Poster
2015 ASCO Annual Meeting
A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas.
First Author: Jennifer Leigh Clarke
Poster
2012 Gastrointestinal Cancers Symposium
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
First Author: Eric Roeland